{
  "extraction_metadata": {
    "timestamp": "2025-09-04T11:18:47.771008",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 5,
    "total_picos": 6
  },
  "picos_by_country": {
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "investigatorâ€™s choice chemotherapy (gemcitabine 1250mg/m2 days 1 and 8 every 21 days, docetaxel 75 mg/m2 day 1 every 21 days, or pemetrexed 500 mg/m2 day 1 every 21 days)",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 7,
      "ContextTokens": 1396
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel or docetaxel plus nintedanib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 33,
      "ContextTokens": 6407
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sotorasib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 3,
      "ContextTokens": 513
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 14,
      "ContextTokens": 3363
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 3307
    }
  }
}